Enhancement of liver size by stimulation of intact rat liver with exogenous hepatotrophic factors

Department of Histology and Embriology of the Instituto de Ciencias Biomédicas of Universidade de São Paulo and II Surgical Division, Medical School of the Pontifícia Universidade Católica, Sorocaba, Brazil

In mammals, liver size is related to animal body weight at the 2.5 to 3% proportion, a ratio mediated by the afflux of hepatotrophic factors. Formulas capable of modifying this ratio have been developed in previous studies on the rat, with enhancement of liver size brought about by intraperitoneal (portal) infusion of exogenous factors such as glucose, amino acids, insulin, glucagon, vitamins, electrolytes, and triiodothyronine. However, the efficacy of these formulations was accompanied by increased animal mortality (PARRA et al.19,20). The present study, which was carried out with small methodological modifications on a larger number of rats using daily intraperitoneal injections of a solution of exogenous hepatotrophic factors (40 ml/kg) for seven days, confirms the previous findings, with a 114.16 ± 7.90% enhancement of liver size beyond the expected value for the body weight of the animal. However, the problem of animal mortality was not fully resolved.

UNITERMS: Glucagon. Insulin. Liver regeneration. Thyroid hormone.

The liver has the ability to regulate its own size according to the trophic “influence” it receives, i.e., according to the afflux of the set of substances and hormones generically called hepatotrophic factors, many of them of splanchnic origin, such as insulin, glucagon, amino acids, vitamins, and certainly many more of still unknown origin. Thus, there is a specific liver size for each animal corresponding to 2.5 to 3% of body weight (2,7,18,24). This relation tends to remain constant through a process of cell multiplication known as regeneration which is activated whenever the organ loses part of its mass due to surgical (hepatectomy) or pathological (necrosis) reasons. The most intimate mechanisms underlying this control are not fully known. They involve modifications in the expression of several genes and the appearance of messenger RNA and its respective protein molecules which represent several other factors having either a stimulatory action such as hepatocyte growth factor (HGF) and transforming growth factor α (α-TGF) or an inhibitory action on this process such as transforming growth factor β (β-TGF) (14,21). In practical terms, there is general acceptance of the existence of an equilibrium between liver size and supply of splanchnic hepatotrophic factors.
Previous studies by our group have demonstrated that this equilibrium can be broken by exogenous supplementation with some known hepatotrophic factors, leading to an increase in intact (non-hepatectomized) liver size beyond the biologically predetermined size (19, 20). The successive formulations developed in these studies have shown an increasing ability to stimulate a regenerative enhancement of liver size, although at the expense of also increasing mortality, thus preventing statistical validation of the data obtained due to the small number of surviving animals. The objective of the present study was to confirm the previous findings using small methodological modifications and a larger number of animals.

**MATERIAL AND METHODS**

Female Wistar rats weighing approximately 200 g were divided into two groups and housed in cages with food and water “ad libitum”. After a 24-hour fast, the animals were identified individually and weighed and then injected daily intraperitoneally with 40 ml/kg of the following solutions:

- **Group A (control, N = 10)** - Saline solution containing carboxymethylcellulose (CMC) at 0.25% concentration.
- **Group B (N = 20)** - a standard solution for parenteral nutrition of the following composition:

  - Glucose 104 g
  - Solution containing the amino acids specified below 200 ml
  - Pyridoxine 2 mg
  - Calcium pantothenate 2 mg
  - Thiamine 30 mg
  - Riboflavin phosphate 4 mg
  - Potassium chloride 1.43 g
  - Sodium bicarbonate 1.50 g
  - Nicotinamide 50 mg
  - Monopotassium phosphate 750 mg
  - Magnesium sulfate 500 mg
  - Vitamin C 500 mg
  - Distilled water q.s 500 ml

  The amino acid solution employed (Soramin 10%, Darrow Laboratorios S.A.), with 16 g/l nitrogen, contained:

  - L-phenylalanine 540 mg
  - L-isoleucine 370 mg
  - L-leucine 980 mg
  - L-lysine, acetate 590 mg
  - L-methionine 530 mg
  - L-threonine 490 mg
  - L-tryptophan 180 mg
  - L-valine 530 mg
  - L-arginine (base) 1060 mg
  - L-histidine (base) 460 mg
  - L-alanine 1030 mg
  - L-asparagine 380 mg
  - L-aspartic acid 270 mg
  - L-glutamic acid 250 mg
  - L-glutamic acid 250 mg
  - L-cystine 30 mg
  - L-arginine 260 mg
  - L-proline 840 mg
  - L-serine 250 mg
  - L-tyrosine 160 mg
  - Glycine 800 mg
  - Distilled water q.s 100 ml

  The following substances were added to each 100 ml of the parenteral feeding solution: 12.5 units of regular insulin (Biobrás-Bioquímica do Brasil), 0.125 mg glucagon (Eli Lilly), 500 µg folic acid, 6.25 µg vitamin B12, 625 µg zinc sulfate, and 250 mg CMC.

  L-triiodothyronine (T3) 2.26 µg/200 g rat weight in ethyl alcohol was placed separately in each syringe containing the solution to prevent T3 precipitation in aqueous medium from interfering with uniform application.

  On the 8th day, the animals were sacrificed by ether inhalation after a 24-hour fast and their body and liver weights were recorded. A liver fragment was obtained, weighed immediately, identified and frozen for later DNA measurement.

  Animal mortality during the experiment was recorded daily after the beginning of the injection schedule and is reported as percent of the total number of animals in each group.

  The variation in liver weight enhancement in group B animals was calculated at the end of the experiment as observed weight minus expected weight divided by expected weight. The latter weight was determined as a function of animal body weight at sacrifice multiplied by the liver weight/body weight ratio factor, defined in group A animals (control). In summary:

  \[
  \text{Variation in liver weight enhancement} = \frac{\text{Observed weight} - \text{Expected weight}}{\text{Expected weight}} \times 100
  \]

  where

  - Expected liver weight = Body weight at sacrifice \times factor obtained for group A


  PARRA, O.M.; SILVA, R.A.P.S.; SILVA, J.R.M.C. e cols. - Enhancement of liver by stimulation of intact rat liver with exogenous hepatotrophic factors
Biochemical DNA measurement was performed after trichloroacetic acid extraction using the diphenylamine reaction (3,18).

Statistical analysis: The results are reported as means ± SEM. Data for the two groups were compared by the Mann-Whitney test when necessary, with the level of significance set at p<0.05.

RESULTS

No mortality was observed in group A animals, whereas mortality was 60% in group B, with a biphasic pattern: the first peak occurred during the first two days (35% of all animals) and a second peak occurred during

Table 1

<table>
<thead>
<tr>
<th>Body weight</th>
<th>Liver weight</th>
<th>Liver weight/body weight</th>
</tr>
</thead>
<tbody>
<tr>
<td>227.2</td>
<td>6.064</td>
<td>0.0266</td>
</tr>
<tr>
<td>221.2</td>
<td>5.242</td>
<td>0.0236</td>
</tr>
<tr>
<td>203.6</td>
<td>5.271</td>
<td>0.0258</td>
</tr>
<tr>
<td>202.8</td>
<td>5.625</td>
<td>0.0277</td>
</tr>
<tr>
<td>201.2</td>
<td>5.526</td>
<td>0.0274</td>
</tr>
<tr>
<td>215</td>
<td>4.990</td>
<td>0.0232</td>
</tr>
<tr>
<td>182.5</td>
<td>4.313</td>
<td>0.0236</td>
</tr>
<tr>
<td>200.4</td>
<td>5.544</td>
<td>0.0276</td>
</tr>
<tr>
<td>194.5</td>
<td>4.655</td>
<td>0.0239</td>
</tr>
<tr>
<td>215.4</td>
<td>5.263</td>
<td>0.0244</td>
</tr>
<tr>
<td>Mean</td>
<td></td>
<td>0.0254</td>
</tr>
<tr>
<td>SEM</td>
<td></td>
<td>±0.0005</td>
</tr>
</tbody>
</table>

Table 2

<table>
<thead>
<tr>
<th>Body weight</th>
<th>Liver weight</th>
<th>Liver weight/body weight</th>
<th>Enhancement of liver size</th>
</tr>
</thead>
<tbody>
<tr>
<td>241.2</td>
<td>10.793</td>
<td>0.0447</td>
<td>76.17</td>
</tr>
<tr>
<td>205.2</td>
<td>10.534</td>
<td>0.0513</td>
<td>102.11</td>
</tr>
<tr>
<td>201</td>
<td>10.329</td>
<td>0.0514</td>
<td>102.32</td>
</tr>
<tr>
<td>193.5</td>
<td>10.304</td>
<td>0.0533</td>
<td>109.65</td>
</tr>
<tr>
<td>205.1</td>
<td>11.199</td>
<td>0.0546</td>
<td>114.97</td>
</tr>
<tr>
<td>212.4</td>
<td>11.960</td>
<td>0.0563</td>
<td>121.69</td>
</tr>
<tr>
<td>227.4</td>
<td>13.951</td>
<td>0.0614</td>
<td>141.54</td>
</tr>
<tr>
<td>200</td>
<td>12.437</td>
<td>0.0622</td>
<td>144.82</td>
</tr>
<tr>
<td>Mean</td>
<td></td>
<td>0.0544</td>
<td>114.16</td>
</tr>
<tr>
<td>SEM</td>
<td></td>
<td>±0.0020</td>
<td>±7.90</td>
</tr>
</tbody>
</table>
the last two days (25% of all animals) (Fig. 1). Table 1 shows the body and liver weights of group A animals at the time of sacrifice and their ratio, which was used to calculate the liver weight/body weight index to be used for the determination of expected liver weight in group B animals.

Table 2 shows the individual values for body weight, liver weight, liver weight/body weight ratio and enhancement of hepatic size in group B survivors. It should be emphasized that two of the animals who died, one on the 6th and the other on the 7th day after the beginning of the injections, having escaped cannibalism on the part of the survivors, could be submitted to autopsy and to the calculation of enhancement of liver size (Table 3).

Table 4 summarizes the results and the statistical comparisons of DNA measurements in animals from the two groups at the time of sacrifice in terms of concentrations in hepatic tissue (mg/g liver) and total DNA/liver (mg).

DISCUSSION

Enhancement of liver size in intact (non-hepatectomized) livers by stimulation with exogenous hepatotrophic factors has been demonstrated in previous studies (19,20) and has been attributed to a regenerative mechanism involving an increase in hepatocyte number.

The major difficulty in the study of increased liver size in experiments in which estimated size is compared to observed mass is to determine estimated size in live animals. This is done indirectly by defining the liver weight/body weight ratio in a group of control animals. This procedure also ties the calculation of liver growth to final body weight, a fact that eliminates the possible influence of treatment with glucose, amino acids and hormones on variations in animal appetite, food consumption and body growth rate (20). The difference between the mean percent enhancement of liver size obtained in the present study (114.16 ± 7.90%) and that

<table>
<thead>
<tr>
<th>Day of death</th>
<th>Body weight (g)</th>
<th>Liver weight (g)</th>
<th>Enhancement of liver size (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>6th</td>
<td>196.9</td>
<td>12.345</td>
<td>146.84</td>
</tr>
<tr>
<td>7th</td>
<td>199.2</td>
<td>11.180</td>
<td>120.57</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Group</th>
<th>DNA concentration (mg/g liver)</th>
<th>Total DNA (mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>2.477 ± 0.060</td>
<td>12.99 ± 0.46</td>
</tr>
<tr>
<td>B</td>
<td>1.765 ± 0.120</td>
<td>20.17 ± 1.44</td>
</tr>
</tbody>
</table>

p=0.0005 p=0.0002
obtained in the previous study (67.54 ± 10.18%) (20) is essentially due to the utilization of a new factor for the liver weight/body weight ratio (0.0254) determined in a specific group of control animals also subjected to intraperitoneal injections of saline solution. The pain and stress of this procedure probably modified through a neurohormonal pathway this ratio which had been previously calculated to be 0.033 in intact animals (18). If the enhancement in liver mass obtained in the present study were calculated as a function of the 0.033 factor (calculations not shown), the mean would be 64.84 ± 0.08%, similar to that obtained previously (20). This change definitely provided a control group of greater scientific rigor.

The association of the factors used here with powerful mitogens for hepatocytes such as epidermal growth factor (EGF) and hepatocyte growth factor (HGF), which have proved to be able to induce by themselves an increase in the size of intact livers in animals (6,16), may possibly induce a better response, perhaps within a shorter period of time.

However, the increase in liver growth achieved with the methodological modifications sequentially introduced in our previous studies (19,20) was accompanied by an also increasing mortality rate, with a biphasic behavior (20), i.e., a first peak during the first two days after the beginning of the injections and a second peak during the last two days. This behavior was repeated in the present experiment (Fig. 1). The two peaks were attributed to different causes, the first being related to a possible initial toxicity of the solutions employed, since it had been observed that a human milk extract added to the solution as the vehicle for growth factors protected the animals (20). This protective action was confirmed by the use of defatted and lyophilized cow's milk, but was accompanied by the onset of non-fatal chemical peritonitis in the animals thus treated (unpublished data). For this reason, in the present study we tried carboxymethylcellulose (CMC) for its protective action, but no effective results were obtained. The administration of the solutions in a more physiological manner by continuous infusion into the portal system, especially in larger animals, into the peritoneal cavity itself and even fractionation of the dose employed into more than one daily intraperitoneal injection may possibly reduce the initial mortality of the experimental animals.

The second mortality peak with an increasing pattern observed during the last days of the previous experiment (20) and also in the present study, was minimized here by the reduction of the number of injection days from 10 to 7, so as to obtain a number of surviving animals whose results could be analyzed statistically without impairment of liver size enhancement. A high rate of liver growth was also observed in the animals that died (Table 3). Studies are currently underway in our laboratory to determine whether this late mortality is related to the increase in liver size, assuming that a maximum limit exists for regenerative liver growth and that this limit was continuously forced by the exogenous hepatotropic stimulus against the biologically predetermined equilibrium.

The increase in liver size was accompanied by a significant dilution in tissue DNA concentration, as indicated in Table 4. Since the report by HIGGINS & ANDERSON (11), it has been known that the parenchyma gains fluid during the late stages of regeneration. Such a great increase in liver size, although accompanied by some degree of variation in tissue composition, does not seem to invalidate our interpretation that its cause is mainly the formation of new cells, in view of the great and significant increase in total DNA mass per liver (from 12.99 mg to 20.17 mg, p = 0.0002). A study of the variations in tissue composition may better elucidate this detail.

The difficulty in maintaining the portal vein catheterized for one week in small animals was obviated by applying the solutions under study intraperitoneally, although accepting some systemic absorption through the abdominal wall. It has been demonstrated that exogenous hepatotropic factors have the highest effect when introduced through the portal vein, mimicking their physiological route, when compared to administration through a peripheral vein (19). We consider this observation
to be very important although it has not been considered before in studies aiming at the treatment of certain liver diseases with the administration of exogenous factors as a regenerative stimulus(1,5,8,15,23).

We believe that the perspective of stimulating liver regeneration by the administration of hepatotrophic factors by the portal route has great clinical applicability both in situations of reduced liver size after hepatectomy or hepatocyte necrosis (hepatitis and abscesses) and in situations involving the intact liver, such as cases of transplants from live donors, providing the recipient with a greater implantable hepatic segment and the donor with a greater residual liver mass. Also, patients with cirrhosis, in whom regenerative stimulation by partial hepatectomy has been shown to produce a histological and functional improvement(4,9,10,12,13,17,22) may benefit from this method without the inconvenience of reduced function brought about by hepatectomy.

RESUMO

Objetivos: Confirmar observações anteriores (PARRA e col. 19,20) que sugeriam a possibilidade de fazer crescer o fígado em animais intactos, por estímulo hepatotrófico exógeno, ultrapassando seu tamanho biologicamente pré-determinado. Material e Métodos: Dois grupos de fêmeas de ratos Wistar, foram injetadas diariamente na cavidade peritoneal (40 ml/kg) por sete dias consecutivos com as seguintes soluções: GRUPO A (controle) - solução salina com carboximetilcelulose (CMC) a 0.25%; GRUPO B - solução de fatores hepatotróficos exógenos constituída de glicose, aminoácidos, insulina, glucagon, vitaminas, elétrólitos, triiodotironina e CMC na mesma concentração do grupo controle. No oitavo dia os animais foram sacrificados e avaliados os seguintes parâmetros: variação da massa hepática e DNA total do fígado dos animais do grupo experimental em relação ao grupo controle. Resultados: Foi observado crescimento da massa hepática de 114,16 ± 7,9% acima do esperado e aumento do DNA total hepático de 12,99 ± 0,46 mg para 20,17 por fígado (p=0.0002). Conclusão: O aumento do tamanho do fígado a partir de sua massa primitiva, estimulada por fatores hepatotróficos exógenos, pode vir a ter aplicações em hepatologia, como em casos de cirroses revertendo parcialmente as alterações histológicas e funcionais, ou em transplantes intra-vivos, criando maior massa hepática a ser dividida entre doador e receptor.
REFERENCES


